India Pharma Monitor

Pharmaceutical Industry in India

Latest Pharma News

June 2026

Alkem Labs – Launched semaglutide in single-shot pre-filled syringes at ₹350 (generic for Ozempic/Wegovy) for diabetes & obesity on June 4, 2026.

Lupin + Natco – Secured US FDA approval for Eribulin Mesylate Injection (1 mg/2 mL) for metastatic breast cancer & liposarcoma; bioequivalent to Halaven Injection, approved on June 3, 2026.

Anthem Biosciences – Received SEBI nod for ₹3,395 crore IPO (entirely OFS by promoters); IPO listed at 26.85% premium at ₹723.10 on BSE/NSE. SEBI approval date: April 8, 2025.

Wockhardt – CDSCO approved ZAYNICH® (Zidebactam/Cefepime) for complicated UTIs & pyelonephritis; India’s breakthrough antibiotic against antimicrobial resistance on May 27, 2026.

Zydus Therapeutics – FDA granted priority review to NDA for saroglitazar to treat primary biliary cholangitis in May 2026.

CDSCO – Mandated strict compliance with revised Schedule M at Pharmac South Expo on June 5, 2026, and directed all stakeholders to establish pharmacovigilance systems.

International Updates

UK Regulatory Authority – Approved Rilzabrutinib for adults with immune thrombocytopenia (blood disorder treatment) in June 2026.

Novo Nordisk – Launched Wegovy weight-loss pill in UAE (second country after US) on June 3, 2026.

Haisco Pharmaceuticals – Cipepofol became the first China-originated innovative IV anesthetic approved by US FDA in June 2026.

Wockhardt – ZAYNICH received FDA approval for complicated urinary tract infections, making it India’s second drug approved in the US in 2026.od this year. Haisco’s Cipepofol became the first China-originated innovative intravenous anesthetic approved by US FDA. Novo Nordisk launched Wegovy weight-loss pill in the UAE on June 3, 2026, marking the second country offering the pill after the US. FDA granted priority review status to Zydus Therapeutics’ NDA for saroglitazar to treat primary biliary cholangitis.

Pharmaceutical pharma and related areas including facility are generating substantial coverage, with recent headlines pointing to active developments around usfda. The Latest Pharma News section brings together the most relevant updates for professionals and stakeholders tracking this segment.

This section aggregates reporting from Sahi, Siliconindia, Barchart.com, and other trusted industry sources. It offers a consolidated view of breaking news, policy updates, and announcements relevant to pharma and related developments.

Readers seeking deeper context may consult IQVIA Pharma Intelligence for regulatory information and PharmaBiz Market Reports for sector analysis and data. For research literature, Reuters Pharmaceuticals provides access to peer-reviewed publications on relevant topics.

Showing 30 articles